• Profile
Close

Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism: A randomized clinical trial

Clinical Journal of the American Society of Nephrology Mar 17, 2021

Shoji T, Nakatani S, Kabata D, et al. - In Japanese patients with secondary hyperparathyroidism undergoing hemodialysis, experts aspired to explore whether calcimimetic agent etelcalcetide is more effective in increasing T 50 value than a vitamin D receptor activator maxacalcitol. Study participants were randomly assigned to obtain intravenous etelcalcetide 5 mg thrice weekly (etelcalcetide group) or intravenous maxacalcitol 5 or 10 µg thrice weekly (maxacalcitol group). A total of 425 patients from 23 dialysis centers were screened for eligibility, 326 patients were randomized (etelcalcetide, n = 167; control, n = 159), and 321 were involved in the intention-to-treat analysis (median age, 66 years; 113 women [35%]). According to this randomized, multicenter, open-label, blinded endpoint trial with active control, in patients on hemodialysis with secondary hyperparathyroidism, etelcalcetide was more effective in increasing T 50 value than maxacalcitol. No difference was found in handgrip strength or cognition between the two drugs.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay